While SUD affects people across all demographics, a growing body of research and clinical experience makes one point clear: gender meaningfully influences how substance use develops, how it is experienced, and what supports effective treatment.
Research from MedCity News and Cotiviti shows robust AI adoption by payers and providers, but what steps are they taking for AI governance and AI weaponized cybersecurity threats?
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.
Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year.
As AI technology in healthcare becomes more deeply involved in the complex, high-stakes tasks of diagnosis and treatment planning, traditional lines of accountability will become less clear. Where does the buck stop for AI-supported medical care?
As a country, we have developed treatments capable of improving the quality of life and preventing long-term damage for children with rheumatic conditions, yet many children cannot obtain them when they need them most. This needs to change.
What are the common reasons that a prototype fails to make the transition? There are several, but they all boil down to early-stage programs ignoring the business problem in favor of the technology problem.
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
When drug prices are too high for patients, physicians take on additional workload to find solutions. A newly released 2026 Physician Drug Cost Survey by RazorMetrics examined how prescription cost pressures affect physicians’ practices.
ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare disease hereditary angioedema, and the RNA therapies pipeline also spans immunological disorders, cardiovascular diseases and obesity, and neurodegeneration.
The question is whether these AI tools will be another fragmented layer of technology or true assistants to help them spend more time on patient care.
CertifyOS launched a shared credentialing program that allows providers to submit their information once for multiple health plans.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
Eli Lilly’s partnership with InnoCare Pharma follows deals struck this year with other China-based companies. While indications for the new alliance remain undisclosed, InnoCare specializes in oncology and autoimmune drugs.
Healthcare has a habit of embracing patient empowerment right up until patients become powerful.
The Centers for Medicare & Medicaid Services (CMS) took constructive steps in its 2027 final rule and rate announcement, particularly on payment integrity and quality measurement. But those steps are not the finish line. Policymakers should further modernize MA to strengthen competition, transparency and accountability. Here’s where to start.
Roche reported the drug sefaxersen achieved statistically significant and clinically meaningful results in a Phase 3 test in immunoglobulin A nephropathy, or IgAN. This antisense oligonucleotide, which came from Ionis Pharmaceuticals, could offer advantages over other drugs currently available for treating this rare chronic disease of the kidneys.
The Series A round was led by .406 Ventures, with support from Emerson Collective (managed by Yosemite), Forerunner, Serena Ventures and Japan-based MPower Partners.